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ORIGINAL ARTICLEOncogene-Expressing Senescent
Melanocytes Up-Regulate MHC Class II,
a Candidate Melanoma Suppressor Function
John van Tuyn1, Farah Jaber-Hijazi1, Douglas MacKenzie1, John J. Cole1, Elizabeth Mann2,
Jeff S. Pawlikowski3, Taranjit Singh Rai4, David M. Nelson1, Tony McBryan1, Andre Ivanov5,
Karen Blyth6, Hong Wu7, Simon Milling2 and Peter D. Adams1,8On acquisition of an oncogenic mutation, primary human and mouse cells can enter oncogene-induced
senescence (OIS). OIS is characterized by a stable proliferation arrest and secretion of proinflammatory
cytokines and chemokines, the senescence-associated secretory phenotype. Proliferation arrest and the
senescence-associated secretory phenotype collaborate to enact tumor suppression, the former by blocking
cell proliferation and the latter by recruiting immune cells to clear damaged cells. However, the interactions of
OIS cells with the immune system are still poorly defined. Here, we show that engagement of OIS in primary
human melanocytes, specifically by melanoma driver mutations NRASQ61K and BRAFV600E, causes expression
of the major histocompatibility class II antigen presentation apparatus, via secreted IL-1ß signaling and
expression of CIITA, a master regulator of major histocompatibility class II gene transcription. In vitro, OIS
melanocytes activate T-cell proliferation. In vivo, nonproliferating oncogene-expressing melanocytes localize
to skin-draining lymph nodes, where they induce T-cell proliferation and an antigen presentation gene
expression signature. In patients, expression of major histocompatibility class II in melanoma is linked to
favorable disease outcome. We propose that OIS in melanocytes is accompanied by an antigen presentation
phenotype, likely to promote tumor suppression via activation of the adaptive immune system.
Journal of Investigative Dermatology (2017) 137, 2197e2207; doi:10.1016/j.jid.2017.05.030INTRODUCTION
Melanoma is a frequently fatal cancer originating from
pigment-producing melanocytes of the skin (Lo and Fisher,
2014). The most common mutations found in melanoma
are those that activate the mitogen-activated protein kinase
signaling pathway, most notably in BRAF and NRAS (Lo and
Fisher, 2014). The same mutations are also commonly found
in benign nevi (or moles) (Omholt et al., 2002; Pollock et al.,
2003). However, benign nevi only rarely progress to cancer
because oncogene-expressing nevus melanocytes are ulti-
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Serrano, 2014). Nevus melanocytes express several molecu-
lar markers of senescence, including senescence-associated
ß-galactosidase (SA ß-gal) and tumor suppressor p16INK4a
(Gray-Schopfer et al., 2006; Michaloglou et al., 2005;
Pawlikowski et al., 2013; Suram et al., 2012). Aggregates of
apparently nonmalignant, nonproliferative, p16INK4a-
expressing, melanocytic nevus-like cells, in the absence of
any concurrent or subsequent melanoma, have also been
well documented in the skin-draining lymph nodes of
humans (Mihic-Probst et al., 2003; Patterson, 2004).
OIS is also characterized by a secretory program, the
senescence-associated secretory phenotype (Acosta et al.,
2008; Krtolica et al., 2001; Kuilman et al., 2008). The
senescence-associated secretory phenotype has various
functions in OIS, including reinforcement and maintenance
of proliferation arrest (Acosta et al., 2008; Kuilman et al.,
2008) and recruitment of macrophages, neutrophils, and
natural killer (NK) cells of the innate immune system to clear
premalignant oncogene-expressing senescent cells (Xue
et al., 2007). NK cells also clear senescent cells in
response to other cell- and tissue-damaging stresses
(Krizhanovsky et al., 2008; Soriani et al., 2009). However,
clearance of mouse hepatocytes expressing an activated
NrasQ61K oncogene was also shown to depend on activa-
tion of adaptive immunity, specifically on CD4þ T cells
(Kang et al., 2011). Typically, CD4þ T cells are activated in
the secondary lymphoid tissues, such as lymph nodes and
spleen, by professional antigen-presenting cells such asestigative Dermatology. This is an open access
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Figure 1. Melanocytes express MHC
class II upon OIS. (a) Staining for SA
ß-gal activity (blue) on vector- or
BRAF600E-transduced melanocytes.
Scale bar ¼ 100 mm. The time span of
oncogene activation was kept at 2
weeks for all OIS experiments
unless indicated otherwise.
(b) Quantification of EdU
incorporation and SA ß-gal staining.
Graph shows means  standard
deviation, n ¼ 3. (c) Representative
RNA sequencing track showing HLA-
DRA sequence reads for control and
BRAFV600E-transduced melanocytes.
Y-axis shows sequence tags per
million tags; x-axis shows position
along the HLA-DRA gene (spanning
5,178 base pairs), with boxed exons.
(d) Detection of HLA-DRA transcript
levels by quantitative real-time reverse
transcriptaseePCR analysis. (e)
Representative immunofluorescent
image of HLA-DRA-GFP (left three
panels) and HLA-DRB-GFP (right
three panels) fusion protein-
transduced melanocytes. GFP staining
in green, staining for MHC class II in
red, and nuclei in blue. Scale bar ¼
200 mm. (f) Western blot showing
BRAF, beta-actin (ATCB), and MHC
class II (HLA-DR) expression.
(g) Confocal immunofluorescent
image of melanocytes stained for
MHC class II (HLA-DR; red) and
nuclei (blue). Scale bar ¼ 10 mm. All
graphs show means  standard
deviation, n ¼ 4. chr, chromosome;
MHC, major histocompatibility; OIS,
oncogene-induced senescence;
SA-Bgal, senescence-associated
b-galactosidase.
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2198dendritic cells (Trombetta and Mellman, 2005). Dendritic
cells endocytose and process antigens in peripheral tissues
and then migrate via the lymphatic vessels to the lymph
nodes, where they activate CD4þ T cells by major histo-
compatibility (MHC) class II-mediated antigen presentation
to naı¨ve T cells.
How senescent cells can activate the adaptive immune
systems has been a mystery. Here we show that OIS in me-
lanocytes caused by activation of the RAS/mitogen-activated
protein kinase pathway is accompanied by dramatic up-
regulation of the MHC class II antigen presentation com-
plex. Furthermore, melanocytes carrying either BrafV600E or
NrasQ61K mutations re-localize specifically to skin-draining
lymph nodes in mouse models. We also present functional
evidence that in the nodes, oncogene-expressingJournal of Investigative Dermatology (2017), Volume 137nonproliferating melanocytes enact an antigen presentation
function to activate the adaptive immune system.
RESULTS
Melanocytes express MHC class II upon oncogene-induced
senescence initiated by melanoma driver mutations
As we and others previously showed (Michaloglou et al.,
2005; Pawlikowski et al., 2013), ectopic expression of
BRAFV600E in primary human melanocytes induces OIS.
Indicative of senescence, BRAFV600E-expressing melano-
cytes up-regulated SA ß-gal (Figure 1a, 1b), arrested DNA
replication as determined by a lack of EdU incorporation
(Figure 1b) and showed senescence-associated heterochro-
matin foci in the nucleus (see Supplementary Figure S1
online).
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melanocytes undergoing OIS by whole-genome microarray
analysis and RNA sequencing (RNA-seq) analysis
(Pawlikowski et al., 2013). Comparing BRAFV600E-
expressing melanocytes against vector-transduced and unin-
fected melanocytes, we observed striking up-regulation of
MHC class II complex transcripts (Figure 1c, Supplementary
Table S1 online). The cell surface of MHC class II complex is
a heterodimer of a and ß polypeptides, for example HLA-
DRA and HLA-DRB1, respectively. Antigen presentation
also depends on expression of chaperones and accessory
factors, such as HLA-DM, HLA-D0, and CD74, which
facilitate antigen processing, loading, and presentation by
the MHC class II complex (Trombetta and Mellman, 2005).
We observed HLA-DRA and HLA-DRB among the top
changes (see Supplementary Table S1). In addition, related
HLA-DQA, HLA-DQB, HLA-DPA, and HLA-DPB were also
up-regulated, together with important antigen processing and
presentation accessory molecules, such as HLA-DMA, HLA-
DMB, and invariant chain CD74 (see Supplementary
Tables S2, S3 online).
Up-regulation of the major components of MHC class II
mRNAs HLA-DRA and HLA-DRB was confirmed by
quantitative real-time reverse transcriptaseePCR
(Figure 1d). Expression of BRAFV600E also enhanced
expression of ectopic HLA-DRA and HLA-DRB GFP fusion
proteins (Figure 1e). Because this increase is independent
of the genes’ normal transcription control elements,
this also suggests at least some level of posttranscriptional
regulation. Expression of endogenous HLA-DR protein
in melanocytes upon OIS was shown by Western blot
analysis (Figure 1f) and immunofluorescence (Figure 1g,
Supplementary Figure S2 online). A significant fraction of
HLA-DR was localized at the plasma membrane of se-
nescent cells (Figure 1g, Supplementary Figure S2b),
consistent with a role in antigen presentation.
To establish whether BRAFV600E-associated MHC class
II expression is cell-type restricted, we transduced mela-
nocytes, primary human fibroblasts (IMR90), and primary
human epidermal keratinocytes with BRAFV600E or con-
trol vector (Figure 2Aa). In contrast to BRAFV600E-
transduced melanocytes, neither fibroblasts nor keratino-
cytes exhibited significant up-regulation of MHC class II
transcript levels (Figure 2b). Furthermore, gene expression
profiling of fibroblasts transduced with BRAFV600E
showed marked down-regulation of proliferation-
promoting genes and up-regulation of inflammatory/
senescence-associated secretory phenotype genes charac-
teristic of senescence (see Supplementary Figure S3 online)
and confirmed no significantly up-regulated MHC class II
genes (see Supplementary Figure S4 online).
These results together suggest that MHC class II induction
is not a common feature of all primary cell types in
response to OIS (fibroblasts) and/or oncogene expression
(keratinocytes).
In addition to activated oncogenes, other triggers also
initiate cell senescence. For example, so-called replicative
senescence, which results from excess rounds of cell division
(Salama et al., 2014). To test whether MHC class II up-
regulation is common to different modes of senescence, weinvestigated replicative senescence melanocytes. Melano-
cytes were serially passaged until they ceased proliferation
and were confirmed to show replicative senescence by pos-
itive staining for SA ß-gal (Figure 2c, 2d) and lack of BrdU
incorporation (Figure 2d). In contrast to BRAFV600E-
mediated OIS, replicative senescence did not induce robust
up-regulation of HLA-DRA or HLA-DRB, as detected by
quantitative real-time reverse transcriptaseePCR (Figure 2e).
Finally, no MHC class II protein could be detected by
Western blotting (data not shown). These findings suggest that
MHC class II induction is specific to OIS in some cell types
and not replicative senescence.
To establish whether MHC class II up-regulation in mela-
nocytes is specific to activated BRAFV600E or also triggered
by other perturbations of melanoma oncogenic and tumor
suppressor pathways, melanocytes were transduced with
activated oncogenes, HRASG12V and NRASQ61K, activated
MEK1Q56P (Emery et al., 2009), and activated myrAKT, as
well as two short hairpin RNAs to stably knock down PTEN
(Figure 2f). Ectopic expression of each of these oncogenes
and knockdown of PTEN resulted in senescence as deter-
mined by positive staining for SA ß-gal (Figure 2g, left, and
see Supplementary Figure S5 online) and lack of proliferation
indicated by the absence of EdU incorporation (Figure 2g,
right). Expression of NRASQ61K, BRAFV600E, and
MEK1Q56P resulted in robust up-regulation of both HLA-
DRA and HLA-DRB, whereas expression of HRASG12V
gave rise to a significantly weaker up-regulation of both. In
marked contrast, myrAKT expression and PTEN knockdown
did not result in detectable HLA-DR up-regulation
(Figure 2h). In contrast to results reported here, PTEN
knockdown has previously been reported to not cause in-
duction of senescence (Vredeveld et al., 2012). There could
be many reasons for this apparent discrepancy—genetic and/
or epigenetic differences in the melanocytes, cell culture
conditions, and others. Regardless, these results suggest that,
at least under conditions used here, MHC class II induction is
specific to aberrant mitogenic signaling through the RAS/
BRAF/ERK pathway but not the PTEN-Akt signaling pathway.
Because MHC class II induction in BRAFV600E mutant
melanocytes occurs concomitantly with induction of senes-
cence, we wished to elucidate whether MHC class II in-
duction is dependent on known effectors of the senescence
program. In human cells, an intact p53 or pRB tumor sup-
pressor pathway is necessary for initiation and maintenance
of the senescence program (Salama et al., 2014), and aboli-
tion of p53/pRB signaling by ectopic expression of SV40
T-antigen disrupts most, if not all, hallmarks of senescence
(Shay et al., 1991). To test whether MHC class II induction is
abolished by ectopic expression of SV40 T antigen, we co-
expressed BRAFV600E together with SV40 T antigen
(Figure 2i). As expected, T-antigen prevented the growth
arrest and SA ß-gal staining associated with senescence in
BRAF-expressing melanocytes (Figure 2j, Supplementary
Figure S6 online). Moreover, co-expression of SV40 T anti-
gen abolished virtually all of the MHC class II induction
(Figure 2k). This suggests that MHC class II induction is not
only initiated by expression of oncogenic BRAFV600E but
requires at least some elements of the p53/pRB-dependent
senescence effector pathways.www.jidonline.org 2199
Figure 2. Expression of MHC class II is specific to melanocytes and OIS. (a) Western blot of BRAFV600E expression in melanocytes, keratinocytes,
and fibroblasts transduced with a vector encoding BRAFV600E (B) or control vector (V). (b) HLA-DRA and HLA-DRB transcript levels detected by
quantitative real-time reverse transcriptaseePCR analysis, in melanocytes (mel), fibroblasts (fib), or keratinocytes (ker). ND indicates no signal detected.
(c) Staining for SA ß-gal activity in melanocytes in exponential growth phase (PD 26) or at replicative senescence (PD 43). Scale bar ¼ 50 mm.
(d) Quantification of SA ß-gale and BrdU-positive melanocytes. (e) HLA-DRA and HLA-DRB transcript levels in melanocytes detected by quantitative
real-time reverse transcriptaseePCR. (f) Western blots of HRASG12V, NRASQ61K, BRAFV600E, MEKQ56P, and myrAKT expression and knockdown
of PTEN. (g) Quantification of SA ß-gal staining (left) and EdU incorporation (right) of melanocytes transduced as indicated. (h) HLA-DRA and
HLA-DRB transcript levels detected by quantitative real-time reverse transcriptaseePCR of melanocytes transduced as indicated. (i) Western blot
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Figure 3. CIITA is a candidate
regulator of MHC class II in OIS
melanocytes. (a) Whole transcriptome
expression correlation network
centered on CIITA generated from The
Cancer Genome Atlas melanoma
RNA sequencing data. Genes are
represented as nodes and a Pearson
Correlation Coefficient (PCC) between
two genes of at least 0.6 as an edge
(n ¼ 375). CIITA is shaded dark red,
and HLA genes are light red. The
boxed highlighted region in the left
panel is shown in the right panel.
(b) Scatterplots of The Cancer Genome
Atlas melanoma RNA sequencing data
comparing the expression of CIITA
versus HLA-DRA (left) and CIITA
versus HLA-DRB1 (right) in 375
patients. (c) Representative University
of California Santa Cruz (UCSC)
genome browser tracks of library
normalized RNA sequencing
expression at HLA-DRA, HLA-DRB1,
and CIITA in seven melanoma cell
lines, melanocytes infected with
BRAFV600E, and uninfected
melanocytes. Y-axis shows sequence
tags per million tags; x-axis shows
position along the HLA-DRA gene,
with boxed exons. (d) Quantitative
real-time reverse transcriptaseePCR
analysis of CIITA transcript levels
detected in melanocytes. Graph
depicts means  standard deviation,
n ¼ 4. (e) CIITA transcript levels
detected by quantitative real-time
reverse transcriptaseePCR. Graph
depicts means  standard deviation,
n ¼ 4. MHC, major histocompatibility
complex; OIS, oncogene-induced
senescence.
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signaling loop
Even though expression of SV40 T antigen suppressed in-
duction of HLA-DRA and HLA-DRB (Figure 2iek), it is well
documented that MHC class II expression is typically found
in 50e60% of freshly isolated melanomas (Taramelli et al.,
1986). We exploited this observation from the melanocytic
lineage to gain insight into candidate regulators of MHC class
II in primary human melanocytes. We assessed the correla-
tion between mRNA expression of HLA-DRA and HLA-DRB
and all other genes in the publicly available skin cutaneousshowing expression of BRAFV600E and SV40 T antigen. (j) Quantification of
BRAFV600E and SV40 T-antigen. (k) All graphs show means  standard dev
senescence-associated b-galactosidase; SA-Bgal, senescence-associated b-gamelanoma gene expression datasets from the Cancer
Genome Atlas (TCGA; http://cancergenome.nih.gov/). This
showed that, across all these datasets, expression of both
HLA-DRA and HLA-DRB correlated most strongly with other
HLA molecules (e.g., HLA-DQ and HLA-DP); other mole-
cules involved in antigen presentation (e.g., CD74); and
CIITA, a transcription factor already known to drive expres-
sion of HLA-DRA and HLA-DRB in dendritic cells (Figure 3a,
3b) (Muhlethaler-Mottet et al., 1997). Conversely, expression
of CIITA correlated most strongly with expression of
MHC class II antigen presentation molecules (Figure 3a, 3b).SA ß-gal staining and EdU incorporation of melanocytes transduced with
iation, n ¼ 4. MHC, major histocompatibility complex; SA ß-gal,
lactosidase.
www.jidonline.org 2201
J van Tuyn et al.
Oncogene-Carrying Melanocytes Activate MHC II
2202To confirm this correlation, we analyzed RNA-seq data from
seven different melanoma-derived cell lines (Pawlikowski
et al., 2013) and found that CIITA transcript levels corre-
lated strongly with HLA-DRA and HLA-DRB levels across this
panel of melanoma lines (Figure 3c). Moreover, we found
that MHC class II induction in melanocytes upon
BRAFV600E-mediated OIS is also accompanied by increased
CIITA expression (Figure 3d). Like expression of MHC class II,
oncogene-induced expression of CIITA was abolished by
SV40 T-antigen (Figure 3e). Consistent with up-regulation of
MHC class II in OIS melanocytes, but not other modes
of senescence (Figure 2), we did not observe up-regulation of
CIITA in OIS fibroblasts (see Supplementary Figure S4).
Together, these data from melanoma tumors, cell lines, and
primary human melanocytes indicate that CIITA is a likely
driver of HLA-DRA and HLA-DRB in OIS primary human
melanocytes.
In cells known to conditionally express CIITA, expression is
frequently induced by extracellular ligands (Trombetta and
Mellman, 2005). Significantly, naı¨ve melanocytes exposed
to medium from OIS melanocytes up-regulated CIITA tran-
scripts (Figure 4a) in conjunction with MHC class II expres-
sion (Figure 4a). To identify the extracellular factors
responsible for up-regulation of CIITA and MHC class II
expression, we probed conditioned medium with an anti-
body array. Medium from BRAFV600E OIS melanocytes
contained increased amounts of inflammatory cytokines
compared with conditioned medium from proliferating cells
(Figure 4b, Supplementary Table S4 online), including IL-1ß
(in the form of either uncleaved pro-IL1ß or cleaved mature
IL-1ß), CCL7, CXCL5, CXCL1, vascular endothelial growth
factor, and CCL5. The presence of one or more IL-1ß (180  9
pg/ml, n ¼ 4) isoforms in the extracellular medium of OIS
melanocytes was confirmed by ELISA (Figure 4c), and robust
up-regulation of IL-1ß mRNA transcripts was detected by
quantitative real-time reverse transcriptaseePCR (Figure 4d).
When added as recombinant proteins to primary human
melanocytes, from a panel of secreted cytokines, only mature
IL-1ß was able to induce CIITA and MHC class II expression
(Figure 4e), but without accompanying activation of senes-
cence, as evidenced by lack of SA ß-gal staining and unim-
peded DNA synthesis (Figure 4f). Conversely, partial
knockdown of IL-1ß using three independent short hairpin
RNAs (Figure 4g) reduced MHC class II induction by
BRAFV600E (Figure 4g). Although we have not formally
confirmed secretion of cleaved mature IL-1ß in this study
(rather than uncleaved proeIL-1ß), previous studies have
shown that OIS cells do secrete processed mature IL-1ß
(Acosta et al., 2013), and IL-1a and IL-1ß are key upstream
regulators of the senescence-associated secretory phenotype
(Acosta et al., 2013; Orjalo et al., 2009). In sum, consistent
with these previous studies, our studies indicate a central role
for extracellular IL-1ß in induction of MHC class II.
We next tested whether IL-1ßemediated up-regulation
of MHC class II also depends on CIITA. In support of this
idea, stimulation of melanocytes with IFN-g, a well-known
inducer of CIITA (Trombetta and Mellman, 2005), also up-
regulated expression of HLA-DRA and HLA-DRB (see
Supplementary Figure S7 online). More pointedly, partial
knockdown of CIITA using two different short hairpinJournal of Investigative Dermatology (2017), Volume 137RNAs (Figure 4h) inhibited HLA-DRA and HLA-DRB
expression induced by recombinant IL-1ß (Figure 4k).
Knockdown of CIITA with two different short hairpin RNAs
also tended to decrease BRAFV600E-induced expression of
HLA-DRA and HLA-DRB, and with the most effective short
hairpin RNA, the effect on HLA-DRB expression was sig-
nificant (P < 0.05) (Figure 4i). The reduced effectiveness of
CIITA knockdown in blocking the effects of activated BRAF
compared with IL-1ß suggests that BRAFV600E can act via
additional signaling effectors besides CIITA. Consistent
with an IL1ß-CIITA-MHC II pathway, ectopic expression of
CIITA was sufficient to induce expression of HLA-DRA and
HLA-DRB, but not IL-1ß, in melanocytes (Figure 4j).
Together, these results indicate that IL-1ßeinduced
expression of CIITA is a major pathway for expression of
MHC class II in OIS melanocytes. BRAFV600E-expressing
fibroblasts up-regulate IL-1ß but neither CIITA nor MHC
II (see Supplementary Figure S4). This suggests that func-
tional coupling between IL-1ß and CIITA occurs in OIS
melanocytes but not fibroblasts.
Oncogene activation causes localization of melanocytes to
lymph nodes and T-cell activation
Previously, a mouse model expressing activated NRASQ61K
in melanocytes under control of a tyrosinase promoter (Tyr-
NrasQ61K) was shown to be hyperpigmented because of an
excess of melanocytes in the skin but also to contain mela-
nocytes in the lymph nodes (Ackermann et al., 2005).
Extending this observation in these mice, we showed that
infiltration of pigmented melanocytes occurs into skin-
draining (Figure 5a, inguinal and brachial) nodes but not
into noneskin-draining nodes (Figure 5a, mesenteric) and
spleen (Figure 5a, spleen). Although immunohistochemical
analysis showed melanotic material dispersed throughout the
skin-draining lymph nodes, particularly in older mice
(Figure 5a), immunofluorescence analysis in lymph nodes of
albino Tyr-NrasQ61K (but not wild-type) mice showed cells
expressing the melanocyte marker DCT and exhibiting den-
dritic features characteristic of melanocytes predominantly
localized adjacent to the subcapsular sinus of the lymph
node (Figure 5b, Supplementary Figure S8a online). There-
fore, to some extent, the melanotic material in the interior
cortex of the node might reflect residual cell debris, including
melanin (oxidized tyrosine polymers), after phagocytic
digestion of melanocytes. To eliminate the possibility that
localization of melanocytes to lymph nodes is unique to Tyr-
NrasQ61K mice, we also confirmed in another mouse model
of inducible BRAFV600E in melanocytes (Tyr-Cre-Er:LSL-
BrafV600E) (Mercer et al., 2005) that 4 weeks after oncogene
activation, predominantly in the skin of young adult mice
(through topical application of tamoxifen), melanocytes also
accumulated in skin-draining brachial and inguinal lymph
nodes (see Supplementary Figure S8b).
As noted previously (Ackermann et al., 2005), compared
with wild-type mice, the lymph nodes of Tyr-NrasQ61K
mice were enlarged (Figure 5c, Supplementary Figure S8c),
and their size progressively increased over at least the first
several months after birth (Figure 5c). Moreover, the
Tyr-NrasQ61K mice exhibited more melanocytes in the
nodes than the Tyr-Cre-Er:LSL-BrafV600E mice (compare
Figure 4. Expression of MHC class II is controlled by an IL-1ßeCIITA loop. (a) qRT-PCR analysis of CIITA and HLA-DRA transcripts in melanocytes exposed to
conditioned medium for 14 days from mock, vector, and BRAFV600E-transduced melanocytes. Graphs depict means standard deviation, n¼ 4. (b) Heat map of
cytokines inconditionedculturemedium.SeeSupplementaryTableS4 for foldchangeandsignificance incytokine levels. (c)QuantificationbyELISAof IL-1ß inconditioned
culture medium. Graph shows mean standard deviation, n¼ 4. *P< 0.0001. (d) qRT-PCR analysis of IL-1ß transcripts. Graphs depict means standard deviation,
n¼ 4. (e) CIITA, HLA-DRA, and HLA-DRB transcripts detected by qRT-PCR of mock or cytokine-treated melanocytes. Cells were cultured for 6 days in culture medium
supplementedwith 10 ng/ml of the indicated cytokine. Graph depicts means standard deviation, n¼ 3. (f) Quantification of EdU incorporation and SA ß-gal staining of
melanocytes. Graphs are means standard deviation, n¼ 4. (g) qRT-PCR analysis of IL-1ß and HLA-DRA transcripts in melanocytes transduced with vector (V) or
BRAFV600E (B) in combination with an shRNA to IL-1ß or nontargeting control (NTC). Graphs depict means standard deviation, n¼ 4. (h) qRT-PCR analysis of CIITA,
HLA-DRA, andHLA-DRB transcripts inmelanocytes inducedwith vehicle or recombinant IL-1ß and transducedwith shRNAs against CIITA or nontargeting control (NTC).
(i) qRT-PCR analysis of CIITA, HLA-DRA, and HLA-DRB transcripts in melanocytes transduced with vector or BRAFV600E and an shRNA against CIITA or nontargeting
control (NTC). Graphs depict means standard deviation, n¼ 4. *P< 0.05. (j) qRT-PCR analysis of CIITA, HLA-DRA, HLA-DRB, and IL-1ß transcript levels in
melanocytes transduced with control vector (V), BRAFV600E (B), or CIITA (C) overexpression vectors. Graphs depict means  standard deviation, n¼ 4. MHC, major
histocompatibility complex; qRT-PCR, quantitative real-time reverse transcriptaseePCR; SA ß-gal, senescence-associated b-galactosidase; shRNA, short hairpin RNA.
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Figure 5. Oncogene-expressing melanocytes localize to skin-draining lymph nodes. (a) Hematoxylin and eosin-stained sections of lymph nodes and spleen of
WT and Tyr-NrasQ61K mice. Scale bar ¼ 100 mm. (b) DCT (green)-expressing cells in lymph node. DAPI, blue. C, cortex; Sub S, subcapsular sinus. Scale
bar ¼ 100 mm. (c) Inguinal lymph node size plotted against age of mouse. Each point is a single node (two nodes per mouse). (d) Melanocytes detected by DCT
(green) in lymph nodes of albino Tyr-NrasQ61K transgenic mice and cycling cells detected by Ki67 (red). Scale bar ¼ 100 mm. (e) Quantification of total
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Oncogene-Carrying Melanocytes Activate MHC IIFigure 5a and Supplementary Figure S8b, NrasQ61K and
BrafV600E), paralleling the relative numbers of melano-
cytes in the skin of each model (Ackermann et al., 2005;
Dhomen et al., 2009).
To determine the proliferative status of the melanocytes in
the lymph nodes, we used two-color immunofluorescence to
stain melanocyte-containing lymph nodes of wild-type and
Tyr-NRasQ61K albino mice for Ki67, a marker of cycling
cells, and DCT, a marker of melanocytes. DCT-positive me-
lanocytes in lymph nodes were invariably Ki67 negative,
whereas large numbers of surrounding lymphocytes stained
positive for Ki67 (Figure 5d). In fact, quantification of the cell
fractions from the nodes, showed a massive expansion of
nonmelanocyte (nonemelanin-containing) cells (Figure 5e,
left) and of CD3þ T cells in particular (Figure 5e, right),
suggesting that the melanocytes present in the lymph nodes,
directly or indirectly, induce a marked activation and
expansion of T cells in these nodes. In sum, the increase in
lymph node size appears to result primarily from expansion
of T-cell populations in melanocyte-containing nodes.
T-cell activation and proliferation can be stimulated by
MHC class II-mediated antigen presentation (Trombetta and
Mellman, 2005). To investigate whether MHC class
II-expressing melanocytes acquire the ability to activate T
cells, we performed the mixed leukocyte reaction in which
antigen-presenting cells stimulate proliferation of T cells.
Indeed, BRAFV600E-expressing OIS melanocytes induced
cell division in Carboxyfluorescein diacetate succinimidyl
esterelabeled CD3þ cells in vitro, much more efficiently than
control melanocytes (2.3-fold, P < 0.0001) (Figure 5f, 5g).
Although this assay using unpurified T cells does not allow us
to attribute T-cell activation to a direct physical interaction
between T cells and MHC II on melanocytes, it does show
that BRAFV600E mutant melanocytes are more able, either
directly by physical interaction or indirectly via other cell
types or secreted factors, to stimulate T cells than are control
melanocytes.
To investigate whether melanocyte-containing lymph
nodes of Tyr-NRasQ61K mice exhibited features of increased
antigen presentation, we harvested RNA from lymph nodes
and performed RNA-seq. This showed up- and down-
regulation of approximately 577 and 423 genes, respec-
tively (see Supplementary Figure S9 online). Remarkably, the
top five gene ontologies represented in the up-regulated
genes of Tyr-NRasQ61K nodes reflected increased antigen
presentation and associated processes, such as endocytosis
and vesicle-mediated transport (Figure 5h, 5i). In principle,
T-cell expansion and antigen presentation in lymph nodes ofnonmelanocyte (nonpigmented, left) and CD3þ fraction (right) from pooled inguina
deviation, n ¼ 3 per group. *7.2-fold difference, P ¼ 0.0049. #5.3-fold difference,
withWBCs (neg, solid line),WBCs incubatedwith LPS (LPS), andmelanocytes tran
shows unstainedWBCs (neg, dotted line). (g) Percentage of replicating CD3þ cells
BRAFV600E-transduced melanocytes. Bars represent means  standard deviation
genes that are up-regulated by RNA sequencing (FDR 5%) in Tyr-NrasQ61K ove
given in h for WT and Tyr-NrasQ61K lymph nodes. Genes are given by column a
indicates more highly expressed and blue indicates more lowly expressed genes. (j
Nuclei are counterstainedwith hematoxylin (blue). Scale bar¼50mm.Quantificati
by calculating the average number positive cells from two slides per lymph node
showed no significant difference between the nodes (160.8 21.1 vs. 174.3 27.6
false discovery rate; ID, identification; LPS, lipopolysaccharide; neg, negative; WBTyr-NrasQ61K mice could be associated with immune acti-
vation or induction of immune tolerance, the latter by acti-
vation of regulatory T cells (Delacher et al., 2014). To
distinguish between these possibilities, we stained lymph
nodes for expression of FoxP3, a transcription factor
expressed by regulatory T cells (Delacher et al., 2014). This
did not show an increase in the frequency of regulatory T
cells in lymph nodes from Tyr-NrasQ61K mice (Figure 5j).
We conclude that oncogene-expressing, nonproliferating
primary melanocytes, directly or indirectly, facilitate an an-
tigen presentation function and potential immune activation
function in the lymph nodes.
To assess the significance of MHC class II expression in
human melanocytic neoplasia, we mined human melanoma
Cancer Genome Atlas data comparing expression of CIITA,
HLA-DRA, and HLA-DRB with patient survival. Remarkably,
high expression of each of these genes predicted improved
patient survival (see Supplementary Figure S10 online).
Moreover, HLA-DRA and HLA-DRB are both components of
the recently defined “immune infiltration” gene expression
signature that is associated with good prognosis in this dis-
ease (The Cancer Genome Atlas Network, 2015; data not
shown). Of course, at least part of the CIITA, HLA-DRA, and
HLA-DRB could be expressed by infiltrating immune cells
themselves. However, previous studies have reported
expression of HLA-DR on melanoma cells (Barbieri et al.,
2011; Colloby et al., 1992; Pollack et al., 1981), and we
also confirmed expression of HLA-DRA, HLA-DRB, and
CIITA in a number of melanoma cell lines (Figure 3c). This
underscores the importance of MHC class II expression in
melanoma and is consistent with a tumor suppressor role for
MHC class II.
DISCUSSION
Here we show that oncogene activation in primary human
melanocytes is accompanied by up-regulation of MHC class
II antigen presentation molecules, and phenotypes and
functions suggestive of an antigen presentation role in vivo.
Up-regulation of MHC class II molecules in OIS melanocytes
is triggered by senescence-associated secretory phenotype
factor IL-1ß, followed by IL-1ßemediated up-regulation of
CIITA, a master regulator of MHC class II expression
(Trombetta and Mellman, 2005).
Several observations suggest that MHC class II expression
in oncogene-expressing melanocytes has a dedicated
function. First, melanocytes are restricted to the skin-
draining nodes, suggesting that they reach the nodes specif-
ically via the lymphatics, the normal route for migration ofl, brachial, and axillary lymph nodes permouse. Graph plots means standard
P ¼ 0.0007. (f) FACS analysis of CSFE levels in CD3þ cells after co-culture
sducedwith vector or BRAFV600E. The plot with the negative sample result also
after induction withWBCs (neg), WBCs incubated with LPS (LPS), and vector or
, n ¼ 4. (h) Table of the five most enriched gene ontologies (FDR  5%) for
r WT lymph nodes. (i) Column clustered heat map of all genes in the ontologies
nd samples by row. The color intensity represents column z-score, where red
) Representative Foxp3 staining (brown) of albinoWTand Tyr-NrasQ61Kmice.
on of the number of positive cells in twoNRAS61Kmice and twoWT littermates,
and counting three lymph nodes (two inguinal, one brachial) per mouse,
, n¼ 2, P¼ 0.83). CSFE, Carboxyfluorescein diacetate succinimidyl ester; FDR,
C, white blood cell; WT, wild type.
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blood. Second, these cells do not appear to be malignant, as
judged by the absence of proliferation and their routine
occurrence in mice lacking any detectable melanoma. Both
the NRas and Braf models exhibit a long latency in progres-
sion to melanoma, of several months to more than a year
(Ackermann et al., 2005; Dhomen et al., 2009). In both
models, melanocytes were detected in nodes months before
any melanoma was detected and is expected (e.g., at 39 days
old). As noted previously, aggregates of apparently nonma-
lignant, nonproliferative, p16INK4a-expressing, melanocytic
nevus-like cells, in the absence of any concurrent or subse-
quent melanoma, have also been reported in the skin-
draining lymph nodes of humans (Mihic-Probst et al., 2003;
Patterson, 2004) (albeit not as frequently or markedly as
observed in the Tyr-NrasQ61K mouse model). Third,
oncogene-expressing primary melanocytes appear to pro-
mote activation of the immune system. Oncogene-expressing
senescent melanocytes stimulated T-cell proliferation in vitro
in the mixed leukocyte reaction assay, and localization of
melanocytes to the nodes was accompanied by a large in-
crease in node-resident CD3þ T cells. RNA-seq analysis of
lymph nodes also showed gene expression signatures char-
acteristic of increased antigen presentation in the
melanocyte-containing lymph nodes of Tyr-NrasQ61K mice.
The increase in T cells was not accounted for by an overt
increase in FoxP3-expressing tolerance-inducing regulatory T
cells. In sum, although we cannot, of course, formally rule
out the possibility that the node melanocytes are very early
and/or failed micrometastases, the collective data from mice
and humans at least suggest the possibility that oncogene-
expressing premalignant melanocytes might be pro-
grammed to activate the adaptive immune system.
Other caveats should also be considered. In general,
benign human nevi do not express MHC II, nor are they
associated with immune infiltration (Campoli et al., 2012;
Lyle et al., 2000). By IHC, we also found that nevi only
very rarely (<10%) express detectable MHC II. Conceivably,
benign human nevi represent a subset of OIS melanocytes
that have been selected for down-regulation of MHC II via
evasion of MHC II-mediated immune- editing. In apparent
contrast to the data presented here, vemurafenib, a
BRAFV600E inhibitor, was previously found to up-regulate
IFN-mediated MHC II expression in A375 melanoma cells
(Sapkota et al., 2013). A wider comparison of the functional
relationship between BRAFV600E and expression of MHC II
in transformed melanoma cells, compared with primary OIS
melanocytes studied here, is justified.
Notwithstanding these caveats and the overall complexity of
immune responses, composed of intricate temporally and
spatially controlled antagonistic and synergistic interactions
between many cell types, these data suggest a model whereby
oncogene-expressing primary melanocytes up-regulate
expression of MHC class II via an IL-1ß/CIITA autocrine
loop. These melanocytes re-localize to the skin-draining
lymph nodes, where they appear able to directly or indi-
rectly stimulate proliferation of T cells. We propose that
the ability of oncogene-expressing primary melanocytes to
engage the adaptive immune system may facilitate tumor
suppression.Journal of Investigative Dermatology (2017), Volume 137MATERIALS AND METHODS
Details of materials and methods are available in the
Supplementary Materials and Methods online (see also
Supplementary Tables S5, S6).
Cell culture
Lightly pigmented neonatal human epidermal melanocytes, human
neonatal epidermal keratinocytes (both from Gibco, Waltham, MA)
IMR90 fibroblasts (ATCC, Manassas, VA) were cultured according to
supplier instructions. Infections with lentiviral vectors were per-
formed as described (Pawlikowski et al., 2013). In all experiments,
oncogene and control vector transduced cells were kept in culture
under selection for 2 weeks before being assayed for senescence and
gene expression. Alternatively, melanocytes were cultured in me-
dium supplemented with 10 ng/ml recombinant growth factor listed
in Figure 4e (all from Gibco, Waltham, MA) for 6 days.
Genetically modified mouse strains
Mice carrying a tyrosinase promoter driven NrasQ61K gene
(Tyr-NrasQ61K) have been described (Ackermann et al., 2005).
Mice conditionally expressing the mutant BrafV600E gene under
control of tyrosinase driven CRE-ER (Delmas et al., 2003) (Tyr-CRE-
ER:LSL-BrafV600E) have also been described (Dhomen et al., 2009).
Albino mice carrying the Tyr-NrasQ61K allele were generated by
cross-breeding with the albino FVB/NJ (Taketo et al., 1991) strain.
Control wild-type mice were littermate albino mice lacking the
Tyr-NRasQ61K transgene. All experiments were carried out in
compliance with UK Home Office guidelines at the Beatson Institute
for Cancer Research (Home Office PCD 60/2607) under project
license 60/4079.
Microarray, RNA-seq, and The Cancer Genome Atlas data
Microarray and RNA-seq analysis of melanocytes transduced with
BRAF600E expression or control vectors has been described
(Pawlikowski et al., 2013); sequences are available from www.ncbi.
nlm.nih.gov/geo (accession nos. GSE46818, GSE99397).
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